News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
854,063 Results
Type
Article (86974)
Company Profile (704)
Press Release (766384)
Multimedia
Podcasts (152)
Webinars (19)
Section
Business (232863)
Career Advice (4133)
Deals (39768)
Drug Delivery (130)
Drug Development (91134)
Employer Resources (199)
FDA (18207)
Job Trends (17372)
News (396943)
Policy (39838)
Tag
Academia (3002)
Academic (2)
Accelerated approval (13)
Adcomms (33)
Allergies (109)
Alliances (56976)
ALS (123)
Alzheimer's disease (1611)
Antibody-drug conjugate (ADC) (192)
Approvals (18160)
Artificial intelligence (407)
Autoimmune disease (39)
Automation (20)
Bankruptcy (406)
Best Places to Work (12633)
BIOSECURE Act (22)
Biosimilars (139)
Biotechnology (482)
Bladder cancer (103)
Brain cancer (41)
Breast cancer (407)
Cancer (3201)
Cardiovascular disease (256)
Career advice (3542)
Career pathing (34)
CAR-T (213)
CDC (43)
Cell therapy (587)
Cervical cancer (25)
Clinical research (74475)
Collaboration (1150)
Company closure (3)
Compensation (733)
Complete response letters (37)
COVID-19 (2913)
CRISPR (70)
C-suite (386)
Cystic fibrosis (124)
Data (3247)
Decentralized trials (2)
Denatured (54)
Depression (83)
Diabetes (384)
Diagnostics (6994)
Digital health (26)
Diversity (10)
Diversity, equity & inclusion (49)
Drug discovery (192)
Drug pricing (155)
Drug shortages (36)
Duchenne muscular dystrophy (159)
Earnings (97779)
Editorial (50)
Employer branding (25)
Employer resources (169)
Events (131625)
Executive appointments (924)
FDA (20071)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (10)
Funding (1039)
Gene editing (152)
Generative AI (41)
Gene therapy (462)
GLP-1 (946)
Government (5283)
Grass and pollen (7)
Guidances (215)
Healthcare (20920)
HIV (46)
Huntington's disease (32)
IgA nephropathy (44)
Immunology and inflammation (193)
Immuno-oncology (13)
Indications (42)
Infectious disease (3118)
Inflammatory bowel disease (166)
Inflation Reduction Act (13)
Influenza (78)
Intellectual property (129)
Interviews (813)
IPO (17907)
IRA (57)
Job creations (5194)
Job search strategy (2863)
Kidney cancer (15)
Labor market (60)
Layoffs (600)
Leadership (27)
Legal (10138)
Liver cancer (85)
Longevity (12)
Lung cancer (448)
Lymphoma (224)
Machine learning (12)
Management (65)
Manufacturing (477)
MASH (104)
Medical device (14749)
Medtech (14755)
Mergers & acquisitions (22606)
Metabolic disorders (978)
Multiple sclerosis (106)
NASH (23)
Neurodegenerative disease (165)
Neuropsychiatric disorders (46)
Neuroscience (2403)
NextGen: Class of 2025 (7687)
Non-profit (5091)
Now hiring (51)
Obesity (497)
Opinion (292)
Ovarian cancer (106)
Pain (128)
Pancreatic cancer (133)
Parkinson's disease (203)
Partnered (25)
Patents (338)
Patient recruitment (186)
Peanut (55)
People (65789)
Pharmaceutical (143)
Pharmacy benefit managers (25)
Phase I (22975)
Phase II (32336)
Phase III (24357)
Pipeline (1784)
Policy (251)
Postmarket research (3554)
Preclinical (10378)
Press Release (72)
Prostate cancer (156)
Psychedelics (46)
Radiopharmaceuticals (279)
Rare diseases (543)
Real estate (7402)
Recruiting (76)
Regulatory (27315)
Reports (62)
Research institute (2667)
Resumes & cover letters (650)
Rett syndrome (10)
RNA editing (12)
RSV (61)
Schizophrenia (103)
Series A (174)
Series B (120)
Service/supplier (30)
Sickle cell disease (69)
Special edition (22)
Spinal muscular atrophy (168)
Sponsored (37)
Startups (4307)
State (2)
Stomach cancer (17)
Supply chain (86)
Tariffs (70)
The Weekly (96)
Vaccines (936)
Venture capital (60)
Weight loss (334)
Women's health (52)
Worklife (20)
Date
Today (136)
Last 7 days (580)
Last 30 days (1980)
Last 365 days (33897)
2025 (19602)
2024 (38139)
2023 (42568)
2022 (53929)
2021 (58724)
2020 (57666)
2019 (51338)
2018 (39124)
2017 (37190)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1277)
Alabama (72)
Alaska (7)
Arizona (281)
Arkansas (14)
Asia (50593)
Australia (8892)
California (8001)
Canada (2480)
China (741)
Colorado (342)
Connecticut (356)
Delaware (215)
Europe (116123)
Florida (1195)
Georgia (273)
Hawaii (3)
Idaho (67)
Illinois (759)
India (34)
Indiana (396)
Iowa (19)
Japan (248)
Kansas (117)
Kentucky (33)
Louisiana (19)
Maine (73)
Maryland (1129)
Massachusetts (6126)
Michigan (280)
Minnesota (498)
Mississippi (4)
Missouri (107)
Montana (32)
Nebraska (26)
Nevada (86)
New Hampshire (74)
New Jersey (2246)
New Mexico (31)
New York (2234)
North Carolina (1267)
North Dakota (10)
Northern California (3470)
Ohio (259)
Oklahoma (17)
Oregon (48)
Pennsylvania (1714)
Puerto Rico (18)
Rhode Island (40)
South America (1654)
South Carolina (36)
South Dakota (1)
Southern California (2977)
Tennessee (132)
Texas (1237)
United States (30192)
Utah (233)
Virginia (220)
Washington D.C. (80)
Washington State (704)
West Virginia (4)
Wisconsin (87)
There are 854,063 results that match your search.
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Diabetes
Lilly’s Mounjaro ‘Good Enough’ in Cardio Trial, Will Seek Expanded Approval
While Eli Lilly’s diabetes blockbuster was non-inferior to its older incretin therapy Trulicity in a highly anticipated Phase III cardiovascular outcomes trial, analysts had hoped for statistical significance in reducing major events such as cardiovascular death, heart attack and stroke.
July 31, 2025
·
2 min read
·
Heather McKenzie
Job Trends
Greener Pastures? 81% of Employed Biopharma Professionals Want New Jobs,
BioSpace
Finds
Employed biopharma professionals are highly likely to look for new jobs in the next 12 months, although not quite as likely as their unemployed counterparts, according to a
BioSpace
LinkedIn poll. Three recruitment experts discuss the findings and what’s driving job searches.
July 31, 2025
·
4 min read
·
Angela Gabriel
IN PARTNERSHIP WITH IQVIA
We Don’t Own Patient Data–We’re Just Babysitting It
In this episode presented by IQVIA, BioSpace’s head of insights Lori Ellis discusses the concerns and opportunities of patient data driving AI tasks with Louise Molloy, associate director medical information and pharmacovigilance.
July 31, 2025
·
1 min read
·
Lori Ellis
Immunology and inflammation
AbbVie Carves Out Niche for Rinvoq With ‘Impressive’ Alopecia Areata Data
Rinvoq’s efficacy in alopecia areata is “impressive,” according to Guggenheim analysts, who said the drug could have a competitive edge over other JAK inhibitors in the space.
July 31, 2025
·
2 min read
·
Tristan Manalac
Alzheimer’s disease
Amyloid Return ‘Slow’ After Stopping Lilly’s Kisunla
Long-term extension data presented at the Alzheimer’s Association International Conference showed amyloid plaque reaccumulation remained slow at up to 2.5 years of follow-up in patients who were taken off of treatment with Eli Lilly’s anti-amyloid antibody.
July 31, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Agios Reports Second Quarter 2025 Financial Results and Provides Business Update
July 31, 2025
·
10 min read
Press Releases
Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results
July 31, 2025
·
22 min read
Press Releases
Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients
July 31, 2025
·
5 min read
Press Releases
BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December
July 31, 2025
·
6 min read
Press Releases
Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025
July 31, 2025
·
1 min read
1 of 85,407
Next
